Status:
TERMINATED
Treatment of Melasma With Yellow Light Compared to Tranexamic Acid
Lead Sponsor:
University of Nove de Julho
Conditions:
Melasma
Eligibility:
FEMALE
35-50 years
Phase:
NA
Brief Summary
Photobiomodulation (PBM) has been suggested as an alternative treatment for Melasma, showed by the in vitro data, inhibition of the tyrosinase enzyme and reduction in the pigment content by autophagy....
Detailed Description
This is a controled, randomized, double blind, two arms clinical trial. The main objective of this study is to evaluate the effect of photobiomodulation with amber light in the treatment of Melasma co...
Eligibility Criteria
Inclusion
- Feminine gender
- Age between 35 to 50 years
- Phototypes l to lV of the Fitzpatrick scale
- Facial melasma
- Healthy participants without clinical skin comorbidities (psoriasis, vitiligo, rosacea and dermatoses)
Exclusion
- Pre-existing systemic diseases, autoimmune diseases, digestive system disease
- Polycystic ovary
- Isotretinoin drug use (less than 6 months)
- Sequelae of an accident on the face that interferes with the facial treatment
- Undertakes any treatment for topical or oral Melasma at the time of the research or less than 3 months ago
- Uses retinoic acid, vitamin A derivatives, photosensitizing drugs
- Skin pathologies on the face
- Glaucoma, cataract, cancer patients, pregnant women, lactating women
- Uses oral or intrauterine contraceptives (IUD)
- Thyroid disorders
- Use of hormone replacement
- Bacterial, viral and fungal infections
- Tendency to form keloids
Key Trial Info
Start Date :
May 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT05326997
Start Date
May 1 2023
End Date
October 30 2023
Last Update
October 21 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Galache Clinic
São Caetano do Sul, São Paulo, Brazil, 09550050
2
Universidade Nove de Julho
São Paulo, Brazil, 01504001